TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05315700: An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Sponsor: ORIC Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 350 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$8,639,400

Rescue Site Savings

+$5,694,150

Unlock Full NCT05315700 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05315700 Rescue Dossier →